On 7th September 2021, Johnson & Johnson Innovation, in collaboration with Janssen Research & Development, LLC’s Oncology Therapeutic Area, will host a virtual scientific and strategic partnering event on state-of-the-art developments in immune cell engagers in hematological malignancies, bringing together entrepreneurs, start-ups, researchers, and scientists from across Europe and beyond.
The discovery and development of T-cell redirecting modalities, such as bispecific antibodies and CAR-Ts, holds great promise for patients with multiple myeloma and other hematological malignancies, such as lymphoma and acute myeloid leukemia.
At Johnson & Johnson Innovation, in order to create transformational curative regimens, we are seeking to nurture new connections and collaborations in pushing the boundaries in immune cell engaging therapeutics. We are working towards comprehensive regimens, synergistic combinations and novel targets, all aimed at intercepting disease and moving towards cures. This next wave of scientific innovation includes:
– Novel engager molecule designs enhancing efficacy and safety
– Discovery of novel tumor specific lineage antigens
– Redirection of alternative immune effector cells (gamma delta T-cells, NK cells)
– Allogenic “off the shelf” cell therapy platforms, such as iPSC derived cell therapies
We are seeking to connect with entrepreneurs, biotechs and academic researchers who aspire to these scientific strategies for a discussion on the next wave of science and innovation in immune engagers. We also want to explore how Johnson & Johnson Innovation could collaborate with the aim to support opportunities and enable innovators and their innovations to reach full therapeutic potential for patients.